Harwin Peter Evan
Insider CIK 1663607 · CBIO Director, 10% owner · MGEN Director · UMRX Director · SYRE Director, 10% owner · DNTH Director, 10% owner · KRSA Director, 10% owner · JBIO Director, 10% owner · DMRA Director, 10% owner · ZBIO Director · APGE Director · ORKA Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KRSA Korsana Biosciences, Inc. | A Award deriv | 2026-09-09 | 2026-09-10 | 48,445 | — | $0 | 48,445 | SEC↗ |
| KRSA Korsana Biosciences, Inc. | A Award deriv | 2026-09-09 | 2026-09-10 | 48,445 | — | $0 | 48,445 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 47,758 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 6,743,321 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 340,855 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 47,758 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 6,743,321 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 340,855 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 31,838 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 10,370 | $43.85 | $454.7K | 340,855 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 31,838 | $17.00 | $541.2K | 330,485 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 31,838 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 10,370 | $43.85 | $454.7K | 340,855 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 31,838 | $17.00 | $541.2K | 330,485 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy deriv | 2026-07-16 | 2026-07-20 | 525,897 | $14.50 | $7.63M | 2,294,037 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy | 2026-07-16 | 2026-07-20 | 853,450 | $14.50 | $12.38M | 3,601,316 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | C Conversion deriv | 2026-07-01 | 2026-07-01 | 42,641 | — | $0 | 94,497 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | C Conversion | 2026-07-01 | 2026-07-01 | 3,553,410 | — | $0 | 4,685,364 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | S Sale | 2026-07-01 | 2026-07-01 | 3,553,410 | $84.43 | $300.01M | 1,131,954 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | C Conversion deriv | 2026-06-23 | 2026-06-23 | 16,667 | — | $0 | 0 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-06-23 | 2026-06-23 | 4,684,781 | $85.31 | $399.66M | 0 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | C Conversion | 2026-06-23 | 2026-06-23 | 666,680 | — | $0 | 4,684,781 | SEC↗ |
| COGT Cogent Biosciences, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 17,901 | — | $0 | 17,901 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 34,843 | — | $0 | 34,843 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award deriv | 2026-06-02 | 2026-06-03 | 9,136 | — | $0 | 9,136 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | A Award deriv | 2026-06-02 | 2026-06-03 | 11,050 | — | $0 | 11,050 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2026-03-31 | 2026-04-01 | 150,000 | $20.00 | $3.00M | 2,359,025 | SEC↗ |
| DMRA Damora Therapeutics, Inc. | A Award deriv | 2026-03-23 | 2026-03-25 | 37,313 | — | $0 | 37,313 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise deriv | 2026-02-09 | 2026-02-12 | 2,904 | — | $0 | 574 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise deriv | 2026-02-09 | 2026-02-12 | 5,809 | — | $0 | 1,148 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise | 2026-02-09 | 2026-02-12 | 2,904,000 | — | $0 | 2,904,000 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise | 2026-02-09 | 2026-02-12 | 5,809,000 | — | $0 | 5,809,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | S Sale | 2026-01-22 | 2026-01-22 | 1,750,000 | $76.30 | $133.53M | 298,647 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy deriv | 2025-12-04 | 2025-12-08 | 131,434 | $13.41 | $1.76M | 1,768,140 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy | 2025-12-04 | 2025-12-08 | 1,360,000 | $13.41 | $18.24M | 2,747,866 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2025-10-07 | 2025-10-09 | 316,219 | $19.00 | $6.01M | 2,209,025 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award deriv | 2025-10-06 | 2025-10-08 | 855,047 | $9.14 | $7.82M | 855,047 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award | 2025-10-06 | 2025-10-08 | 1,333,126 | $9.14 | $12.18M | 1,897,677 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award | 2025-09-17 | 2025-09-19 | 333,340 | $15.00 | $5.00M | 1,131,954 | SEC↗ |
| CBIO GLYCOMIMETICS INC | A Award deriv | 2025-06-23 | 2025-06-23 | 9,023 | — | $0 | 9,023 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2025-06-17 | 2025-06-20 | 14,461 | — | $0 | 14,461 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2025-06-17 | 2025-06-20 | 14,461 | — | $0 | 14,461 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | A Award deriv | 2025-06-10 | 2025-06-12 | 18,500 | — | $0 | 18,500 | SEC↗ |
| COGT Cogent Biosciences, Inc. | A Award deriv | 2025-06-04 | 2025-06-05 | 44,700 | — | $0 | 44,700 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award deriv | 2025-06-02 | 2025-06-03 | 17,500 | — | $0 | 17,500 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2025-05-29 | 2025-06-02 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2025-05-29 | 2025-06-02 | 25,000 | — | $0 | 25,000 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award deriv | 2025-04-29 | 2025-05-01 | 23,017 | — | $0 | 23,017 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | M Exercise deriv | 2024-11-19 | 2024-11-21 | 160 | — | $0 | 0 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | M Exercise | 2024-11-19 | 2024-11-21 | 160,000 | — | $0 | 798,614 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 357,143 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 2,614,287 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 6,163,236 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 2,195,871 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 357,143 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 2,195,871 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 6,163,236 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 2,614,287 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 41,130 | — | $0 | 41,140 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 252,890 | — | $0 | 294,020 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 709,794 | — | $0 | 1,003,814 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2024-09-16 | 2024-09-16 | 300,000 | $17.00 | $5.10M | 1,604,891 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 301,077 | — | $0 | 1,304,891 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2024-09-16 | 2024-09-17 | 300,000 | $17.00 | $5.10M | 1,892,806 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 41,130 | — | $0 | 329,045 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 252,890 | — | $0 | 581,935 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 301,077 | — | $0 | 1,592,806 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 709,794 | — | $0 | 1,291,729 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | A Award deriv | 2024-09-12 | 2024-09-16 | 37,000 | — | $0 | 37,000 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | A Award deriv | 2024-09-12 | 2024-09-17 | 37,000 | — | $0 | 37,000 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award deriv | 2024-09-11 | 2024-09-13 | 160 | $23000.00 | $3.68M | 160 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award | 2024-09-11 | 2024-09-13 | 275,000 | $23.00 | $6.33M | 638,614 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2024-06-26 | 2024-06-28 | 21,000 | — | $0 | 21,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2024-06-05 | 2024-06-07 | 10,370 | — | $0 | 10,370 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2024-06-05 | 2024-06-07 | 10,370 | — | $0 | 10,370 | SEC↗ |
| COGT Cogent Biosciences, Inc. | A Award deriv | 2024-06-05 | 2024-06-13 | 44,700 | — | $0 | 44,700 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2024-05-14 | 2024-05-16 | 11,323 | — | $0 | 11,323 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2024-05-14 | 2024-05-16 | 11,323 | — | $0 | 11,323 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | M Exercise deriv | 2024-04-25 | 2024-04-25 | 90,992 | — | $0 | 346,045 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | M Exercise | 2024-04-25 | 2024-04-25 | 3,639,680 | — | $0 | 4,018,101 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other deriv | 2024-03-28 | 2024-04-01 | 221,426 | — | $0 | 6,743,321 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other deriv | 2024-03-28 | 2024-04-01 | 221,426 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-03-28 | 2024-04-01 | 55,913 | — | $0 | 2,048,647 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-03-28 | 2024-04-01 | 55,913 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-01-29 | 2024-01-31 | 51,166 | — | $0 | 51,166 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-01-29 | 2024-01-31 | 892,529 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-01-29 | 2024-01-31 | 51,166 | — | $0 | 51,166 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | A Award deriv | 2024-01-22 | 2024-01-24 | 832,333 | $12.00 | $9.99M | 832,333 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | A Award | 2024-01-22 | 2024-01-24 | 834,334 | $12.00 | $10.01M | 2,762,837 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | J Other | 2023-12-29 | 2023-12-29 | 3,435,480 | — | $0 | 0 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | J Other | 2023-12-29 | 2023-12-29 | 406,038 | — | $0 | 406,038 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | J Other | 2023-12-29 | 2023-12-29 | 406,038 | — | $0 | 406,038 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2023-12-07 | 2023-12-11 | 16,667 | $600.00 | $10.00M | 16,667 | SEC↗ |
| AGLE Spyre Therapeutics, Inc. | C Conversion deriv | 2023-11-24 | 2023-11-28 | 85,887 | — | $0 | 0 | SEC↗ |
| AGLE Spyre Therapeutics, Inc. | C Conversion | 2023-11-24 | 2023-11-28 | 3,435,480 | — | $0 | 3,435,480 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | P Buy | 2023-09-29 | 2023-10-03 | 24,670 | $13.63 | $336.3K | 1,928,503 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | P Buy | 2023-09-26 | 2023-09-28 | 30,000 | $13.15 | $394.5K | 1,903,833 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | P Buy | 2023-09-19 | 2023-09-21 | 30,000 | $13.20 | $396.0K | 1,873,833 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | P Buy | 2023-09-13 | 2023-09-13 | 9,367 | $11.76 | $110.2K | 1,843,833 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | P Buy | 2023-09-12 | 2023-09-13 | 14,887 | $10.85 | $161.5K | 1,834,466 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | A Award deriv | 2023-09-11 | 2023-09-13 | 6,500 | — | $0 | 6,500 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2023-07-13 | 2023-07-17 | 47,758 | — | $0 | 47,758 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2023-07-13 | 2023-07-17 | 47,758 | — | $0 | 47,758 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2023-07-13 | 2023-07-17 | 892,529 | $17.00 | $15.17M | 892,529 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2023-07-13 | 2023-07-17 | 1,992,734 | $17.00 | $33.88M | 1,992,734 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2023-07-13 | 2023-07-17 | 55,913 | $17.00 | $950.5K | 55,913 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2023-06-14 | 2023-06-16 | 20,000 | — | $0 | 20,000 | SEC↗ |
| COGT Cogent Biosciences, Inc. | A Award deriv | 2023-06-07 | 2023-06-08 | 36,700 | — | $0 | 36,700 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2022-06-08 | 2022-06-10 | 12,500 | — | $0 | 12,500 | SEC↗ |
| COGT Cogent Biosciences, Inc. | A Award deriv | 2022-06-07 | 2022-06-09 | 30,700 | — | $0 | 30,700 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2021-06-03 | 2021-06-16 | 12,500 | — | $0 | 12,500 | SEC↗ |
| COGT Cogent Biosciences, Inc. | A Award deriv | 2021-03-11 | 2021-03-15 | 60,000 | — | $0 | 60,000 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2021-02-04 | 2021-02-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| MGEN MIRAGEN THERAPEUTICS, INC. | A Award deriv | 2020-10-27 | 2020-10-29 | 24,000 | — | $0 | 24,000 | SEC↗ |
| UMRX Unum Therapeutics Inc. | A Award deriv | 2020-08-27 | 2020-08-31 | 28,661 | — | $0 | 28,661 | SEC↗ |